Stocks and Investing
Stocks and Investing
Tue, March 2, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Vikram Purohit Maintained (AXSM) at Buy with Increased Target to $104 on, Mar 2nd, 2021
Vikram Purohit of Morgan Stanley, Maintained "Axsome Therapeutics, Inc." (AXSM) at Buy with Increased Target from $101 to $104 on, Mar 2nd, 2021.
Vikram has made no other calls on AXSM in the last 4 months.
There are 2 other peers that have a rating on AXSM. Out of the 2 peers that are also analyzing AXSM, 0 agree with Vikram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Vikram
- Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $129 on, Friday, January 8th, 2021
- Vamil Divan of "Mizuho" Initiated at Strong Buy and Held Target at $120 on, Wednesday, December 16th, 2020
Contributing Sources